Beximco Pharma - eine Perle aus Bangladesch? (Seite 43)
eröffnet am 16.05.07 14:31:40 von
neuester Beitrag 12.02.24 17:39:26 von
neuester Beitrag 12.02.24 17:39:26 von
Beiträge: 559
ID: 1.127.474
ID: 1.127.474
Aufrufe heute: 0
Gesamt: 69.241
Gesamt: 69.241
Aktive User: 0
ISIN: US0885792061 · WKN: A0ETTX · Symbol: BXP
0,3650
GBP
0,00 %
0,0000 GBP
Letzter Kurs 26.04.24 London
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9000 | +305,04 | |
| 1,3254 | +82,86 | |
| 0,6500 | +25,75 | |
| 6,0000 | +25,00 | |
| 56,69 | +20,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,1200 | -12,17 | |
| 8,5000 | -15,00 | |
| 0,7300 | -18,59 | |
| 92,06 | -19,84 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 36.676.344 von audili am 01.03.09 15:22:22Aktueller Kurs von Beximco 164,00 Taka = 1,88 Euro 
Ich kenne keinen Grund für diesen Kursabschlag. Man kann wohl nur abwarten, bis der Kurs bei uns wieder so hoch wie an der Heimatbörse ist. Es gab ja Zeiten, da war der Kurs bei uns sogar höher.
Für uns ist wichtig, dass es Investoren gibt, die für eine Kapitalerhöhung den vielfachen Preis bezahlen, den die Aktie bei uns kostet. Die werden schon wissen, wie viel Beximco wert ist:
BEXIMCO PHARMACEUTICALS LTD.
News Release
March 5 2009
SEC Consent to GEM Placing
Further to the announcement of 19 February 2009, Beximco announces that the Securities and Exchange Commission has accorded its consent under the provisions of the Securities and Exchange Commission (Issue of Capital) Rules 2001, for the issuance of 16,000,000 Ordinary Shares of Tk 10 each at an issue price up to Tk 312.50 per share (including a premium up to Tk 302.50 per share) and Warrants to subscribe for a maximum 2,500,000 Ordinary Shares of Tk 10 each at an issue price at Tk 200 per share (including a premium of Tk 190 per share), through a private placement with GEM Global Yield Fund Limited.
For further enquiries please contact:
Libertas Capital
Aamir Quraishi / Anthony Rowland
Tel: +44 (0)20 7569 9650
Financial Dynamics
David Yates / Susan Quigley
Tel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.
The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.
This information is provided by RNS
The company news service from the London Stock Exchange
END
Ich kenne keinen Grund für diesen Kursabschlag. Man kann wohl nur abwarten, bis der Kurs bei uns wieder so hoch wie an der Heimatbörse ist. Es gab ja Zeiten, da war der Kurs bei uns sogar höher.
Für uns ist wichtig, dass es Investoren gibt, die für eine Kapitalerhöhung den vielfachen Preis bezahlen, den die Aktie bei uns kostet. Die werden schon wissen, wie viel Beximco wert ist:
BEXIMCO PHARMACEUTICALS LTD.
News Release
March 5 2009
SEC Consent to GEM Placing
Further to the announcement of 19 February 2009, Beximco announces that the Securities and Exchange Commission has accorded its consent under the provisions of the Securities and Exchange Commission (Issue of Capital) Rules 2001, for the issuance of 16,000,000 Ordinary Shares of Tk 10 each at an issue price up to Tk 312.50 per share (including a premium up to Tk 302.50 per share) and Warrants to subscribe for a maximum 2,500,000 Ordinary Shares of Tk 10 each at an issue price at Tk 200 per share (including a premium of Tk 190 per share), through a private placement with GEM Global Yield Fund Limited.
For further enquiries please contact:
Libertas Capital
Aamir Quraishi / Anthony Rowland
Tel: +44 (0)20 7569 9650
Financial Dynamics
David Yates / Susan Quigley
Tel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.
The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.
This information is provided by RNS
The company news service from the London Stock Exchange
END
Antwort auf Beitrag Nr.: 36.675.408 von Crsus am 01.03.09 09:58:05also ich verstehe das nicht mehr, warum ist der europaeische Kurs so schlecht???
Sollte man jetzt nochmal nachlegen? Oder gibt es irgendeinen Grund, warum die europ. Aktien schlechter sind als die am Heimatmarkt oder in den USA???
Sollte man jetzt nochmal nachlegen? Oder gibt es irgendeinen Grund, warum die europ. Aktien schlechter sind als die am Heimatmarkt oder in den USA???
Antwort auf Beitrag Nr.: 36.628.209 von Crsus am 22.02.09 10:20:12Aktueller Kurs von Beximco 153,80 Taka = 1,77 Euro
Beximco hat seit Jahresbeginn immerhin um 12,7 % zugelegt!
Beximco hat seit Jahresbeginn immerhin um 12,7 % zugelegt!
Antwort auf Beitrag Nr.: 36.590.756 von Crsus am 17.02.09 00:23:18Aktueller Kurs von Beximco 157,90 Taka = 1,80 Euro
Umsatz heute 1,2 Mio. Aktien
Auch bei der Bank of New York ist der Kurs stabil bei 2,32 USD
In Deutschland und London ist das Abgeld jetzt schon bei ca. 95 % !
Umsatz heute 1,2 Mio. Aktien
Auch bei der Bank of New York ist der Kurs stabil bei 2,32 USD
In Deutschland und London ist das Abgeld jetzt schon bei ca. 95 % !
Antwort auf Beitrag Nr.: 36.590.519 von uwwu am 16.02.09 22:48:21London ist schon eine komische Börse:
Geldkurs 0,10 GBP, Briefkurs 0,13 GBP und Umsatz mit 0,05 GBP.
Denke mal, da haben sich Grossaktionäre (evtl. Fonds) die Aktien übertragen, warum gerade zu diesem Kurs, wird ihr Geheimnis bleiben.
Geldkurs 0,10 GBP, Briefkurs 0,13 GBP und Umsatz mit 0,05 GBP.
Denke mal, da haben sich Grossaktionäre (evtl. Fonds) die Aktien übertragen, warum gerade zu diesem Kurs, wird ihr Geheimnis bleiben.
Trading Spotlight
In London wurden heute gut 3 Mio. Beximco Pharma GDR gehandelt. Der Preis betrug angeblich 0,05 Pfund (6 Cent).
Nicht nur, dass dies ca. 12 % aller verfügbaren GDR wären, der Preis lag zudem auch über 50 % unter dem Tiefstkurs (Low) des Tages. Die deutschen Börsen (B, F) ziehen natürlich prompt den Geldkurs nach unten. Damit aber niemand kaufen kann, wird der Briefkurs natürlich oben gelassen. Der Spread beträgt jetzt ca. 100 %.
Mit diesem Wertpapier stimmt einiges nicht. Sobald ich die Möglichkeit habe, werde ich die GDR in Originale tauschen, auch wenn kein Handel damit von D aus möglich ist. In Dhaka ist sie heute wieder gestiegen.
http://www.londonstockexchange.com/en-gb/pricesnews/prices/s…
Nicht nur, dass dies ca. 12 % aller verfügbaren GDR wären, der Preis lag zudem auch über 50 % unter dem Tiefstkurs (Low) des Tages. Die deutschen Börsen (B, F) ziehen natürlich prompt den Geldkurs nach unten. Damit aber niemand kaufen kann, wird der Briefkurs natürlich oben gelassen. Der Spread beträgt jetzt ca. 100 %.
Mit diesem Wertpapier stimmt einiges nicht. Sobald ich die Möglichkeit habe, werde ich die GDR in Originale tauschen, auch wenn kein Handel damit von D aus möglich ist. In Dhaka ist sie heute wieder gestiegen.
http://www.londonstockexchange.com/en-gb/pricesnews/prices/s…
Antwort auf Beitrag Nr.: 36.535.745 von Crsus am 08.02.09 10:48:08Nichts Neues, aktueller Kurs von Beximco 159,90 Taka = 1,81 Euro
Antwort auf Beitrag Nr.: 36.489.210 von Crsus am 01.02.09 09:15:22Aktueller Kurs von Beximco 162,50 Taka = 1,83 Euro
Ich hätte nie gedacht, dass sich ein Abgeld von über 90 % über so lange Zeit halten kann, aber in Zeiten der Finanzkrise ist wohl alles möglich.
Ich hätte nie gedacht, dass sich ein Abgeld von über 90 % über so lange Zeit halten kann, aber in Zeiten der Finanzkrise ist wohl alles möglich.
Antwort auf Beitrag Nr.: 36.457.292 von Crsus am 27.01.09 14:43:01Aktueller Kurs von Beximco 170,00 Taka = 1,92 Euro
Am Donnerstag hat Beximco sogar intraday ein Allzeithoch
von 177,60 Taka = 2,00 Euro erreicht.
Die Kapitalerhöhung wurde also von der Börse gut aufgenommen.
Das Abgeld in Deutschland jetzt schon über 90 % !!!
Am Donnerstag hat Beximco sogar intraday ein Allzeithoch
von 177,60 Taka = 2,00 Euro erreicht.Die Kapitalerhöhung wurde also von der Börse gut aufgenommen.
Das Abgeld in Deutschland jetzt schon über 90 % !!!
Antwort auf Beitrag Nr.: 36.450.449 von Crsus am 26.01.09 16:24:13BEXIMCO PHARMACEUTICALS LTD.
News Release
January 27, 2009
Private Placing to GEM Global Yield Fund Limited
Beximco Pharmaceuticals Limited ("BPL" or the "Company"), the leading pharmaceutical manufacturer and the largest pharmaceutical exporter from Bangladesh, announces further details in respect of the anticipated private placing of shares to GEM Global Yield Fund Limited ("GEM"), announced earlier yesterday.
BPL has signed a Subscription Agreement (the "Agreement") that enables it to issue ordinary shares up to Tk.4,100,000,000 (approximately £44.6m) ("Placing Shares") to GEM over the next three years through a number of allotments (the "Allotments") following the issue of Draw Down Notices by BPL. The Agreement states that the number of shares that can be placed in each Allotment is calculated by reference to the average volume of shares traded in the preceding 15 days period, as published by the Dhaka Stock Exchange Limited ("DSE"). The price per share at each Allotment is calculated by reference to the average price per share in the 15-day period following the issue of a Draw Down Notice by BPL, discounted to 90% (the Variable Pricing Method).
The Company also intends to issue a further 2,500,000 warrants to GEM at an exercise price of Tk.200 (approximately £2.17). The warrants will have an exercise period of three years.
The Placing Shares and warrants shall be issued to GEM under section 155(2) of the Companies Act, 1994 (Bangladesh) subject to:
Approval of its shareholders at an Extraordinary General Meeting ("EGM") to be held on Thursday, 19 February 2009 at 10:00 AM at 1 Shahbagh Avenue, Dhaka-1000; and
The consent of the Securities and Exchange Commission ("SEC") thereto under the Securities and Exchange Commission (Issue of Capital) Rules, 2001.
BPL will submit its application to the SEC only after EGM approval is secured. SEC consent is expected to take 4 weeks.
The Company currently has 125,957,747 ordinary shares in issue. Assuming Placing Shares are issued under the Agreement at the current share price of TK166 per share and the warrants are exercised in full, this would result in approximately 27,198,795 new ordinary shares representing 17.76% of the enlarged share capital of the Company. If the Placing Shares are issued at a higher price, fewer shares will need to be issued and dilution will be reduced accordingly.
It is intended that the funds raised by the issue of Placing Shares and warrants will be used by BPL for its Balancing, Modernisation, Replacement and Expansion program ("BMRE"), diversification and working capital.
The Company's vice-chairman, Salman F. Rahman said: "We expect to increase turnover and net profit substantially as a result of this additional funding and resultant capacity increase, to Tk.10,006,000,000 (approximately £108.8m) and Tk 2,030,000,000 (approximately £22.1m) respectively in 2010. We anticipate that most of the additional turnover and profit will come from exports."
An exchange rate of Tk.92:£1 has been used in the above announcement.
News Release
January 27, 2009
Private Placing to GEM Global Yield Fund Limited
Beximco Pharmaceuticals Limited ("BPL" or the "Company"), the leading pharmaceutical manufacturer and the largest pharmaceutical exporter from Bangladesh, announces further details in respect of the anticipated private placing of shares to GEM Global Yield Fund Limited ("GEM"), announced earlier yesterday.
BPL has signed a Subscription Agreement (the "Agreement") that enables it to issue ordinary shares up to Tk.4,100,000,000 (approximately £44.6m) ("Placing Shares") to GEM over the next three years through a number of allotments (the "Allotments") following the issue of Draw Down Notices by BPL. The Agreement states that the number of shares that can be placed in each Allotment is calculated by reference to the average volume of shares traded in the preceding 15 days period, as published by the Dhaka Stock Exchange Limited ("DSE"). The price per share at each Allotment is calculated by reference to the average price per share in the 15-day period following the issue of a Draw Down Notice by BPL, discounted to 90% (the Variable Pricing Method).
The Company also intends to issue a further 2,500,000 warrants to GEM at an exercise price of Tk.200 (approximately £2.17). The warrants will have an exercise period of three years.
The Placing Shares and warrants shall be issued to GEM under section 155(2) of the Companies Act, 1994 (Bangladesh) subject to:
Approval of its shareholders at an Extraordinary General Meeting ("EGM") to be held on Thursday, 19 February 2009 at 10:00 AM at 1 Shahbagh Avenue, Dhaka-1000; and
The consent of the Securities and Exchange Commission ("SEC") thereto under the Securities and Exchange Commission (Issue of Capital) Rules, 2001.
BPL will submit its application to the SEC only after EGM approval is secured. SEC consent is expected to take 4 weeks.
The Company currently has 125,957,747 ordinary shares in issue. Assuming Placing Shares are issued under the Agreement at the current share price of TK166 per share and the warrants are exercised in full, this would result in approximately 27,198,795 new ordinary shares representing 17.76% of the enlarged share capital of the Company. If the Placing Shares are issued at a higher price, fewer shares will need to be issued and dilution will be reduced accordingly.
It is intended that the funds raised by the issue of Placing Shares and warrants will be used by BPL for its Balancing, Modernisation, Replacement and Expansion program ("BMRE"), diversification and working capital.
The Company's vice-chairman, Salman F. Rahman said: "We expect to increase turnover and net profit
substantially as a result of this additional funding and resultant capacity increase, to Tk.10,006,000,000 (approximately £108.8m) and Tk 2,030,000,000 (approximately £22.1m) respectively in 2010. We anticipate that most of the additional turnover and profit will come from exports."An exchange rate of Tk.92:£1 has been used in the above announcement.
Durchsuchen
